Inconsistencies in Opioid Equianalgesic Ratios: Clinical and Research Implications

REFERENCES

• World Health Organization. Cancer Pain Relief, 2nd ed. World Health Organization, GenevaSwitzerland 1996
   Google Scholar
• Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001; 22: 672–687
   PubMed Web of Science ®Google Scholar
• Anderson R, Saiers J H, Abram S, Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 2001; 21: 397–406
   PubMed Web of Science ®Google Scholar
• Patanwala A E, Duby J, Waters D, Erstad B L. Opioid conversions in acute care. Ann Pharmacother 2007; 41: 255–267
   Google Scholar
• Gammaitoni A R, Fine P, Alvarez N, McPherson M L, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003; 19: 286–297
   Google Scholar
• Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol 1998; 16: 3216–3221
   PubMed Web of Science ®Google Scholar
• Jacox A, Carr D B, Payne R, et al. Management of cancer pain. Agency for Health Care Policy and U.S. Research Department of Health and Human Services, Public Health Service, Rockville, MD 1994, Clinical practice guidelines No. 9. AHCPR Publication No 94-0592
   Google Scholar
• Duragesic Prescribing Information. Janssen Pharmaceutica Products, L.P., Titusville, NJ February, 2005
   Google Scholar
• Epocrates Tables: Opioid Equivalents. Epocrates Essentials Version 1.0. Epocrates, Inc. 2003–2007. San Mateo, CA 2007
   Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Center for Cancer Pain Research's opioid conversion program, http://www.hopweb.org/ Accessed September 4, 2007
   Google Scholar
• Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th ed. American Pain Society, Glenview, IL 2003
   Google Scholar
• Nissen L M, Tett S E, Cramond T, Williams B, Smith M T. Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. Br J Clin Pharmacol 2001; 52: 693–698
   Google Scholar
• Post-White J, Kinney M E, Savik K, et al. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther 2003; 2: 332–344
   PubMedGoogle Scholar
• Wilkie D J, Kampbell J, Cutshall S, et al. Effects of massage on pain intensity, analgesics and quality of life in patients with cancer pain: a pilot study of a randomized clinical trial conducted within hospice care delivery. Hospice J 2000; 15: 31–53
   PubMedGoogle Scholar
• Cleeland C S, Ryan K M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med 1994; 23: 129–138
   PubMedGoogle Scholar
• Galer B S, Jensen M P. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997; 48: 332–338
   PubMed Web of Science ®Google Scholar
• Jensen T S, Gottrup H, Sindrup S H, Bach F W. The clinical picture of neuropathic pain. Eur J Pharmacol 2001; 429: 1–11
   PubMed Web of Science ®Google Scholar
• Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995; 6(Suppl 3)39–43
   PubMedGoogle Scholar
• Foley K M, Houde R W. Methadone in cancer pain management: individualize dose and titrate to effect. J Clin Oncol 1998; 16: 3213–3215
   Google Scholar
• Beaver W T, Wallenstein S L, Rogers A, Houde R W. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978; 207: 101–108
   Google Scholar
• Sawe J, Dahlstrom B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629–635
   PubMed Web of Science ®Google Scholar
• Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64: 527–534
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254–261
   PubMed Web of Science ®Google Scholar
• Watanabe S, Pereira J, Hanson J, Bruera E. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Manage 1998; 16: 323–326
   Google Scholar
• Lawlor P G, Turner K S, Hanson J, Bruera E D. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998; 82: 1167–1173
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898–2904
   PubMed Web of Science ®Google Scholar
• Tse D M, Sham M M, Ng D K, Ma H M. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 2003; 17: 206–211
   PubMed Web of Science ®Google Scholar
• Bruera E, Palmer J L, Bosnjak S, Rico M A, Moyano J, Sweeney C, Strasser F, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22: 185–192
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37–45
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998; 16: 3222–3229
   PubMed Web of Science ®Google Scholar
• Lauretti G R, Oliveira G M, Pereira N L. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003; 89: 2027–2030
   PubMed Web of Science ®Google Scholar
• Stamer U M, Stüber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007; 20: 478–484
   PubMed Web of Science ®Google Scholar
• Cleary J F. The pharmacologic management of cancer pain. J Palliat Med 2007; 10: 1369–1394
   PubMed Web of Science ®Google Scholar